Arch Therapeutics, Inc.

Demonstration of AC5® Topical Gel in Porcine Full-Thickness Surgical Wound Models

View Wound Care Demonstration Video

New York City based Investor Summit

Recent Webcast

Innovative Technology

Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.

View MOA Video

Clinical Trial Published

AC5 (T45K) in patients undergoing dermatologic surgery.

Download Article Here

Arch Therapeutics

Transforming the landscape of advanced interventional wound care

Arch Therapeutics is developing innovative self-assembling barrier technologies to improve wound care outcomes, enhance the quality of patient care by healthcare personnel, and offer compelling options to healthcare institutions facing limited resources.

Recent News View All News

:
Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in Europe
:
Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain
ARTH
OTCQB
Price
Volume
Market Cap
Change

About

Learn more about Arch Therapeutics and
its leadership team, poised to meet the challenges of applying innovative biotechnology to develop advanced interventional wound care products.

Learn More

Technology

The wound care market seeks products that work better, faster, & more reliably. See how Arch Therapeutics’ platform can address those needs.

Learn More

Pipeline

Find out more about Arch Therapeutics’ product candidates.

Learn More